Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Stephen B. Hanauer(Northwestern University), Jean‐Frédéric Colombel(Mount Sinai Hospital), William J. Sandborn(University of San Diego), Richmond Sy, Brian G. Feagan(Western University), Geert D’Haens(Amsterdam University Medical Centers), Shomron Ben‐Horin(Tel Aviv University), Jing Xu(Kunming Medical University), Maria Rosario(Millennium Engineering and Integration (United States)), Paul Rutgeerts(KU Leuven), Catherine Milch(Millennium Engineering and Integration (United States)), Asit Parikh, Irving H. Fox(Takeda (United States))
Cited by 714
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k